Latania Y. Booker, Titilope A. Ishola, Kanika A. Bowen and Dai H. Chung Pages 112 - 117 ( 6 )
Neuroblastoma is the third most common pediatric cancer in the United States and is responsible for 15% of childhood cancer-related deaths. Despite major advances in multimodal therapy, the clinical outcome for several patients remains poor. Due to the desperate need for innovativation and improved success in the treatment and management of neuroblastoma, research interests in immunotherapy have been on the rise in recent years. Current immunotherapeutic approaches under investigation include antibodies targeting the neuroblastoma antigen GD2, cytokine stimulation of immune cells, use of immunocytokine conjugates, radioimmunotherapy, and tumor-primed dendritic cells. Immunotherapy could serve as a safe alternative or adjunct to current therapeutic protocols and would presumptively have fewer deleterious effects making it more favorable to patients.
Neuroblastoma, immunotherapy, cell-mediated therapy, antibody-mediated therapy, cytokine-mediated therapy
Section of Pediatric Surgery, Children's Hospital, Suite 3.220-E, The University of Texas Medical Branch, 301 University Boulevard, Galveston, Texas 77555-0353, USA.